Inactief instrument

Andere talen Context Therapeutics Inc.

Aandelen

US21077P1084

Geschatte realtime Cboe BZX Andere beurzen 18:19:27 08-07-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,865 ^USD	-85,65%		0,00%	0,00%

08/05	Context Therapeutics Inc. Rapporteert winstresultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
02/05	Context Therapeutics kondigt aan dat de FDA de IND aanvraag voor een Fase 1 Klinische Studie van CTIM-76 heeft goedgekeurd	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results	08/05
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05
Context Therapeutics Inc. announced that it has received $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	06/05
Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76	02/05
Context Therapeutics Inc. announced that it expects to receive $99.992767 million in funding from Ally Bridge Group, Avidity Partners, LLC, Blue Owl Healthcare Opportunities, Deep Track Capital, LP, Driehaus Capital Management LLC, Great Point Partners, LLC	01/05
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	01/04
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc	06/03
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update	10-08-23
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09-08-23
Context Therapeutics to Participate in Two August 2023 Investor Conferences	01-08-23
Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update	13-06-23
Traders Insights: These Biotech Stocks On Radar: VSTM, SNTX, CGEN, SONN	06-06-23
CONTEXT THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	02-06-23
Testicular Cancer Pipeline Assessment, FDA Approvals, Clinical Trials, Emerging Drugs, and Therapeutics Assessment 2023 \| Major Companies - Sanofi, Seagen Inc., BioNTech, Seagen, and Others	16-05-23
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10-05-23
Context Therapeutics CTIM-76 bispecific antibody preclinical data presented at AACR Annual Meeting	24-04-23
CONTEXT THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	22-03-23
CONTEXT THERAPEUTICS INC. : Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities (form 8-K)	22-03-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Context Therapeutics Inc.

Aandelen

US21077P1084

Andere talen

Filters